title: Letter to the editor.
authors.affiliation: Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada.
authors.forename: Yigal Paul
authors.initials: YP
authors.lastname: Goldberg
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Cohen
authors.forename: Rostam
authors.initials: R
authors.lastname: Namdari
authors.forename: Nicola
authors.initials: N
authors.lastname: Price
authors.forename: Jay A
authors.initials: JA
authors.lastname: Cadieux
authors.forename: Clint
authors.initials: C
authors.lastname: Young
authors.forename: Robin
authors.initials: R
authors.lastname: Sherrington
authors.forename: Simon Neil
authors.initials: SN
authors.lastname: Pimstone
mesh_terms: D004916:Erythromelalgia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D026941:Sodium Channel Blockers / Q000627:therapeutic use*; D015222:Sodium Channels / Q000235:genetics*
chemical_list: D026941:Sodium Channel Blockers; D015222:Sodium Channels